Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone

Human Psychopharmacology

Volumn 29, Issue 1, 2014, Pages 38-45

  Roffeei, Siti Norsyuhada ^a   Reynolds, Gavin P ^b   Zainal, Nor Zuraida ^a   Said, Mas Ayu ^a   Hatim, Ahmad ^a   Aida, Syarinaz Ahmad ^a   Mohamed, Zahurin ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

1291C G adrenergic receptor; 1298A C methylenetetrahydrofolate reductase; antipsychotic induced weight gain; aripiprazole; schizophrenia; ziprasidone

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALPHA 2A ADRENERGIC RECEPTOR; ARIPIPRAZOLE; CHLORPROMAZINE; FLUPENTIXOL; FLUPHENAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; SULPIRIDE; TRIFLUOPERAZINE; ZIPRASIDONE;

ADULT; AGED; ALLELE; ARTICLE; BODY MASS; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MIDDLE AGED; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; YOUNG ADULT;

-1291C/G ADRENERGIC RECEPTOR; 1298A/C METHYLENETETRAHYDROFOLATE REDUCTASE; ANTIPSYCHOTIC-INDUCED WEIGHT GAIN; ARIPIPRAZOLE; SCHIZOPHRENIA; ZIPRASIDONE;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PIPERAZINES; POLYMORPHISM, GENETIC; QUINOLONES; RECEPTORS, ADRENERGIC, ALPHA-2; SCHIZOPHRENIA; THIAZOLES; WEIGHT GAIN; WEIGHT LOSS;

EID: 84892593544     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2366     Document Type: Article

References (47)

1. Allison DB, Mentore JL, Heo M, et al,. 1999. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156: 1686-1696.
2. Alptekin K, Hafez J, Brook S, et al,. 2009. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. Int Clin Psychopharmacol 24: 229-238.
3. American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders, 4th edn, text revision. American Psychiatric Association: Washington, DC.
4. Arner P,. 1992. Adrenergic receptor function in fat cells. Am J Clin Nutr 55: 228S-236S.
5. Bailey LB, Gregory JF,. 1999. Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. J Nutr 129 (5): 919-922.
6. Chagnon YC, Bureau A, Gendron D, et al,. 2007. Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine. Am J Med Genet B Neuropsychiatr Genet 144B: 1063-1069.
7. Chen Y, Bobo WV, Watts K, Jayathilake K, Tang T, Meltzer HY,. 2012. Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidaemia: A 12-month, prospective, open-label study. J Psychopharmacol 26: 1201-1210.
8. Cheng C, Chiu HJ, Loh EW, et al,. 2012. Association of the ADRA1A gene and the severity of metabolic abnormalities in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 36: 205-210.
9. Clifton PG, Lee MD, Dourish CT,. 2000. Similarities in the action of Ro 60-0175: A 5-HT2C receptor agonist and D-fenfluramine on feeding patterns in the rat. Psychopharmacology (Berl) 152: 256-267.
10. Coccurello R, Moles A,. 2010. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: Clues for understanding obesity and novel drug design. Pharmacol Ther 127: 210-251.
11. Correll CU, Lencz T, Malhotra AK,. 2011. Antipsychotic drugs and obesity. Trends Mol Med 17: 97-107.
12. De Vry J, Schreiber R,. 2000. Effects of selected serotonin 5-HT(1) and 5HT(2) receptor agonists on feeding behavior: possible mechanisms of action. Neurosci Biobehav Rev 24: 341-353.
13. Devlin AM, Ngai YF, Ronsley R, Panagiotopoulos C,. 2012. Cardiometabolic risk and the MTHFR C677T variant in children treated with second-generation antipsychotics. Transl Psychiatry 2: e71.
14. Dourish CT, Hutson PH, Curzon G,. 1985. Characteristics of feeding induced by the serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT). Brain Res Bull 15: 377-384.
15. Ellingrod VL, Miller DD, Taylor SF, Moline J, Holman T, Kerr J,. 2008. Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr Res 98: 47-54.
16. Fontecave M, Atta M, Mulliez E,. 2004. S-adenosylmethionine: nothing goes to waste. Trends Biochem Sci 29: 243-249.
17. Garenc C, Pérusse L, Chagnon YC, et al,. 2002. The Alpha2-adrenergic receptor gene and body Fat content and distribution: the HERITAGE family study. Mol Med 8: 88-94.
18. Gregoor JG, van der Weide J, Loovers HM, van Megen HJ, Egberts TC, Heerdink ER,. 2011. Polymorphisms of the LEP, LEPR and HTR2C gene: obesity and BMI change in patients using antipsychotic medication in a naturalistic setting. Pharmacogenomics 12: 919-923.
19. Grundy SM, Cleeman JI, Daniels SR, et al,. 2005. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, And Blood Institute Scientific Statement. Circulation 112: 2735-2752.
20. Hellstrom L, Reynisdottir S, Langin D, Rossner S, Arner P,. 1996. Regulation of lipolysis in fat cells of obese women during long-term hypocaloric diet. Int J Obes Relat Metab Disord 20: 745-752.
21. Jassim G, Ferno J, Theisen FM, et al,. 2011. Association study of energy homeostasis genes and antipsychotic-induced weight gain in patients with schizophrenia. Pharmacopsychiatry 44: 15-20.
22. Kim SW, Shin IS, Kim JM, Bae KY, Yang SJ, Yoon JS,. 2010. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia. Clin Neuropharmacol 33: 121-125.
23. Kuo PH, Kao CF, Chen PY, et al,. 2011. Polymorphisms of INSIG2, MC4R, and LEP are associated with obesity- and metabolic-related traits in schizophrenic patients. J Clin Psychopharmacol 31: 705-711.
24. Lecklin A, Etu-Seppala P, Stark H, Tuomisto L,. 1998. Effects of intracerebroventricularly infused histamine and selective H1, H2 and H3 agonists on food and water intake and urine flow in Wistar rats. Brain Res 793: 279-288.
25. Lett TAP, Wallace TJM, Chowdhury NI, Tiwari AK, Kennedy JL, Muller DJ,. 2012. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry 17: 242-266.
26. Li JL, Canham RM, Vongpatanasin W, Leonard D, Auchus RJ, Victor RG,. 2006. Do allelic variants in alpha2A and alpha2C adrenergic receptors predispose to hypertension in blacks? Hypertension 47: 1140-1146.
27. Masand PS,. 2000. Weight gain associated with psychotropic drugs. Expert Opin Pharmacother 1: 377-389.
28. Miyamoto S, Duncan GE, Marx CE, Lieberman JA,. 2005. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10: 79-104.
29. Montes JM, Rodriguez JL, Balbo E, et al,. 2007. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry 31: 383-388.
30. Panariello F, De Luca V, De Bartolomeis A,. 2011. Review article: weight gain, schizophrenia and antipsychotics: New findings from animal model and pharmacogenomic studies. Schizophr Res Treatment 2011: 459284.
31. Park YM, Chung YC, Lee SH, et al,. 2006. Weight gain associated with the alpha2a-adrenergic receptor -1291 C/G polymorphism and olanzapine treatment. Am J Med Genet B Neuropsychiatr Genet 141B: 394-397.
32. Reynolds GP,. 2012. Pharmacogenetic aspects of antipsychotic drug-induced weight gain-a critical review. Clin Psychopharmacol Neurosci 10: 71-77.
33. Reynolds GP, Kirk SL,. 2010. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther 125: 169-179.
34. Reynolds GP, Zhang ZJ, Zhang XB,. 2002. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 359: 2086-2087.
35. Risselada AJ, Vehof J, Bruggeman R, et al,. 2010. Association between the 1291 -C/G polymorphism in the adrenergic α-2a receptor and the metabolic syndrome. J Clin Psychopharmacol 30: 667-671.
36. Rosmond R, Bouchard C, Bjorntorp P,. 2002. A C-1291G polymorphism in the alpha2A-adrenergic receptor gene (ADRA2A) promoter is associated with cortisol escape from dexamethasone and elevated glucose levels. J Intern Med 251: 252-257.
37. Rossi A, Vita A, Tiradritti P, Romeo F,. 2008. Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone. Int Clin Psychopharmacol 23: 216-222.
38. Sickert L, Muller DJ, Tiwari AK, et al,. 2009. Association of the alpha 2A adrenergic receptor -1291C/G polymorphism and antipsychotic-induced weight gain in European-Americans. Pharmacogenomics 10: 1169-1176.
39. Stahl SM, Mignon L, Meyer JM,. 2009. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 119: 171-179.
40. Takeuchi H, Uchida H, Suzuki T, Watanabe K, Kashima H, 2010. Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study. Psychiatry Clin Neurosci 64: 104-106.
41. Templeman LA, Reynolds GP, Arranz B, San L, 2005. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 15: 195-200.
42. Umbricht DS, Pollack S, Kane JM, 1994. Clozapine and weight gain. J Clin Psychiatry 55: 157-160.
43. Wang YC, Bai YM, Chen JY, Lin CC, Lai IC, Liou YJ,. 2005. Polymorphism of the adrenergic receptor alpha 2a -1291C/G genetic variation and clozapine-induced weight gain. J Neural Transm 112: 1463-1468.
44. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R,. 1998. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64: 169-172.
45. van Winkel R, Moons T, Peerbooms O, et al,. 2010a. MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study. Int Clin Psychopharmacol 25: 270-276.
46. van Winkel R, Rutten BP, Peerbooms O, Peuskens J, van Os J, De Hert M,. 2010b. MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr Res 121: 193-198.
47. Zhang XY, Tan YL, Zhou DF, et al,. 2007. Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population. J Clin Psychopharmacol 27: 246-251.